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Hyperglycemia and Oxidative Stress Strengthen the
Association Between Myeloperoxidase and Blood Pressure
Leonard P. Van der Zwan, Peter G. Scheffer, Jacqueline M. Dekker, Coen D.A. Stehouwer,
Robert J. Heine, Tom Teerlink
Abstract—Scavenging of the vasodilator nitric oxide by myeloperoxidase activity in the vasculature may contribute to
hypertension. Because hydrogen peroxide is a cosubstrate of myeloperoxidase, hyperglycemia-induced oxidative stress
may strengthen the relationship between myeloperoxidase and blood pressure. We investigated this relationship and its
modification by hyperglycemia and oxidative stress in a population-based cohort of elderly subjects with normal glucose
metabolism (n267), impaired glucose metabolism (n189), and type 2 diabetes (n290). In an age- and sex-adjusted
linear regression model, plasma myeloperoxidase was positively associated with systolic blood pressure (2.10 mm Hg
per 1 SD increment of myeloperoxidase [95% CI: 0.66 to 3.54]), and this association was stronger at higher levels of
fasting glucose (0.61 [1.70 to 2.93], 1.33 [1.43 to 4.10], and 3.42 [1.01 to 5.82] for increasing tertiles of glucose)
and higher plasma levels of oxidized low-density lipoprotein (0.92 [1.31 to 3.14], 2.00 [0.71 to 4.70], and 3.58 [0.98
to 6.19] for increasing tertiles of oxidized low-density lipoprotein). Likewise, the relationship between myeloperoxidase
and blood pressure was strongest under conditions associated with oxidative stress, like obesity, low high-density
lipoprotein cholesterol, metabolic syndrome, and type 2 diabetes. The strength of these associations was only marginally
attenuated by adjustment for other cardiovascular risk factors. Our data demonstrate that myeloperoxidase is positively
and independently associated with blood pressure, and this association is strongest in subjects with (hyperglycemia-
induced) oxidative stress. These observations, together with emerging evidence that myeloperoxidase-derived oxidants
contribute to the initiation and propagation of cardiovascular disease, identify myeloperoxidase as a promising target for
drug development. (Hypertension. 2010;55:1366-1372.)
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Increasing evidence suggests that inflammation plays a rolein the development of hypertension.1 Myeloperoxidase
(MPO) is an enzyme linked to both inflammation and
oxidative stress, but the relationship between MPO and blood
pressure remains largely untested. Release of MPO by neu-
trophils and monocytes during inflammation plays an impor-
tant role in the innate immune response,2 but MPO activity
may also lead to tissue damage and precipitate atherogenesis.3
Many studies have demonstrated that systemic MPO levels
predict risk throughout the spectrum of cardiovascular dis-
eases.4–8 MPO catalyzes the production of hypochlorous acid
and a range of other highly reactive species. These MPO-
derived reactive substances may damage the arterial wall,
thereby reducing its elasticity. In addition, by several mech-
anisms, MPO reduces the bioavailability of the endogenous
vasodilator nitric oxide.3,9 Together, these mechanisms may
lead to an increase in blood pressure. Because hydrogen
peroxide is an obligate cosubstrate of MPO, the activity of
MPO in the vasculature may be enhanced by increased local
production of reactive oxygen species. Vascular production
of superoxide and its dismutation product hydrogen peroxide
has been shown to be stimulated by high glucose concentra-
tions, resulting in increased activity of MPO.10 We therefore
hypothesize that the relationship between MPO and blood
pressure is stronger on a background of (hyperglycemia-
induced) oxidative stress.
The aims of our study were to assess the relationship
between plasma levels of MPO and blood pressure and to test
the hypothesis that this relationship is strengthened by
(hyperglycemia-induced) oxidative stress.
Methods
Subjects
The present study was conducted in the Hoorn Study11 follow-up
examination conducted in 2000 and the Hoorn Screening Study,12
both of which are population-based studies in a white population.
From the 822 participants, we excluded subjects with missing data
on primary variables of interest, leaving 746 subjects, of whom 267
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had a normal glucose metabolism, 189 had an impaired glucose
metabolism, and 290 had type 2 diabetes, according to WHO 1999
criteria.13 The local ethics committee approved the study, and all
participants gave their written informed consent.
Blood Pressure Measurement
Subjects were in a sitting position and had rested for 5 minutes
before measurement of systolic (SBP) and diastolic (DBP) blood
pressure. A random-zero sphygmomanometer (Hawksley-Gelman,
Lansing, Sussex, United Kingdom) was used for duplicate measure-
ments, and mean values were used in analyses. Hypertension was
defined as SBP 140 mm Hg or DBP 90 mm Hg, according to
criteria described in the seventh report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure.14
Biochemical Analyses
A sandwich enzyme-linked immunosorbent assay (Mercodia, Upp-
sala, Sweden) was used to determine MPO concentrations in EDTA-
plasma, with intra- and interassay coefficients of variation of 3.9%
and 5.0%, respectively.15 Plasma C-reactive protein (CRP) concen-
trations were determined with a highly sensitive in-house sandwich
enzyme-linked immunosorbent assay.16 Circulating plasma oxidized
low-density lipoprotein (LDL) was determined by competitive
enzyme-linked immunosorbent assay (Mercodia, Uppsala, Swe-
den).17 Hemoglobin A1c (HbA1c) was analyzed by ion-exchange
high-performance liquid chromatography (reference range, 4.3 to
6.1%) on a modular monitoring system (Bio-Rad, Veenendaal, The
Netherlands). Glucose was measured enzymatically (Roche, Mann-
heim, Germany), and insulin was determined by a 2-site immunora-
diometric assay (Medgenix Diagnostics, Fleurus, Belgium). Total
and high-density lipoprotein (HDL) cholesterol and triglycerides
were measured by standard enzymatic methods (Roche). LDL-cho-
lesterol concentration was determined with a direct method by the
“N-geneous” assay (GenZyme, Cambridge, Mass). With this
method, a triglyceride concentration up to 13.5 mmol/L does not
interfere with measurement of LDL-cholesterol.
Microalbuminuria, Metabolic Syndrome, and
Cardiovascular Disease
Microalbuminuria was defined as urinary albumin/creatinine ratio
2.0 mg/mmol. Metabolic syndrome was defined according to the
Adult Treatment Panel III of the National Cholesterol Education
Program, ie, 3 or more of the following: fasting glucose
6.1 mmol/L, HDL-cholesterol 1.03 mmol/L (men) or
1.29 mmol/L (women), triglycerides 1.7 mmol/L, waist circum-
ference 102 cm (men) or 88 cm (women), and blood pressure
130/85 mm Hg.18 Prior cardiovascular disease was defined as
Minnesota Code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 on the ECG19;
coronary bypass operation or angioplasty; an ankle-brachial blood
pressure index 0.9 in either leg; peripheral arterial bypass; or
amputation for atherosclerotic disease.
Statistics
Data are presented as mean and SD or, if skewed, median and
interquartile range. Bivariate associations were assessed by cal-
culation of the Spearman . Skewed variables were natural log
transformed before trend analyses and linear regression analyses.
Statistical significance for linear trend across tertiles of MPO was
calculated by linear regression, with adjustment for age and sex,
or by linear-by-linear 2 tests. Multivariable linear regression
analysis was used to assess the relationship between (log-
transformed) MPO and blood pressure. Confounding by other risk
factors was investigated by adding these factors one by one to
age- and sex-adjusted models and by investigating fully adjusted
models including all risk factors. Regression coefficients were
expressed as change in blood pressure (mm Hg) per SD increase
of log-transformed MPO. Because the variance of MPO did not
significantly differ (tested with the Levene test for homogeneity
of variance) between the various strata investigated, the SD of the
entire population was used for all stratified analyses. Data were
analyzed using SPSS software, version 15 (SPSS Inc., Chicago,
IL). A 2-tailed probability value 0.05 was considered to indicate
statistical significance.
Results
Population Characteristics
Of the 746 study participants 432 (58%) were hypertensive.
After adjustment for age and sex, it was found that blood
pressure, prevalence of hypertension, and use of antihyper-
tensive medication significantly increased across tertiles of
MPO (Table 1). Higher tertiles of MPO were associated with
higher CRP levels, and also, if MPO was analyzed as a
continuous variable, a significant association with CRP was
observed (0.29; P0.001). HbA1c, fasting glucose, and
insulin levels also increased in parallel with MPO, but the
percentage of individuals with type 2 diabetes and impaired
glucose metabolism was not significantly different between
MPO tertiles. Body mass index (BMI), waist circumference,
and prior cardiovascular disease significantly increased with
higher MPO levels, but no significant relationships with lipid
levels (including oxidized LDL) or the use of lipid-lowering
medication were observed.
Association Between MPO and Blood Pressure
Linear regression analysis was used to investigate the rela-
tionship between MPO levels and SBP (Table 2) and DBP
(Table 3). In the entire cohort, MPO was significantly
associated with SBP and DBP, both in crude analysis and
after adjustment for age and sex. Additional adjustment of the
age- and sex-adjusted models for a range of potentially
confounding risk factors, including use of antihypertensive
medication and CRP, only marginally altered the strength of
these associations.
Modification of the Relationship Between MPO
and Blood Pressure by Glucose
Because we hypothesized that the adverse impact of MPO
on blood pressure might be enhanced by hyperglycemia,
we also examined the relationship between MPO and blood
pressure in strata of fasting glucose. In individuals with
glucose levels in the lowest tertile, MPO was not signifi-
cantly associated with SBP ( [95% CI] of 1.04 [1.38 to
3.46] mm Hg per 1-SD increase of MPO), but this associ-
ation was stronger in individuals with intermediate glucose
levels (1.88 [0.83 to 4.59]) and most prominent in
individuals with fasting glucose in the highest tertile (3.82
[1.39 to 6.26]; Table 2). A similar trend across tertiles of
fasting glucose was observed for the relationship between
MPO and DBP (Table 3). The associations of MPO with
both SBP and DBP were hardly influenced by adjustment
for age, sex, and potentially confounding risk factors.
Notably, in subjects with glucose in the highest tertile,
only MPO and age contributed significantly to the fully
adjusted models for SBP and DBP.
In support of the effect of fasting glucose on the association
between MPO and blood pressure, the age- and sex-adjusted
association between MPO and SBP was weak and nonsignif-
icant in subjects with normal or impaired glucose metabolism
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(0.48, P0.70, and 1.36, P0.33, respectively) but
much stronger and highly significant in subjects with type 2
diabetes (3.35; P0.004) (Figure 1). Likewise, the rela-
tionship between MPO and DBP was nonsignificant in
subjects with normal glucose metabolism (0.06;
P0.94) but stronger and significant in subjects with im-
paired glucose metabolism or type 2 diabetes (1.75,
P0.027, and 1.18, P0.047, respectively) (Figure 1).
To further clarify whether the relationship between MPO
and blood pressure was strengthened by hyperglycemia or by
insulin resistance, we also examined the association between
MPO and SBP in strata of HbA1c and insulin. The age- and
sex-adjusted association was weak and nonsignificant in the
lowest tertile of HbA1c ( [95% CI] of 0.26 [2.15 to 2.68])
but much stronger for the intermediate and highest HbA1c
tertiles (3.01 [0.30 to 5.71] and 2.66 [0.17 to 5.16], respec-
tively). In contrast, the association between MPO and SBP
was only marginally influenced by levels of insulin (age- and
sex-adjusted  values of 1.37 [1.45 to 4.18], 1.62 [0.68 to
3.91], and 2.38 [0.11 to 4.88] for increasing tertiles of
insulin).
Influence of Oxidative Stress on the Relationship
Between MPO and Blood Pressure
The fact that the relationship between MPO and blood
pressure was strongest in the presence of high levels of
glucose and that oxidized LDL is associated with glucose
(0.11; P0.003) is in accordance with the hypothesis that
MPO activity is enhanced by (glucose-induced) oxidative
stress, but it does not exclude involvement of nonoxidative
effects of glucose. To gain better insight in the effect of
oxidative stress on the relationship between MPO and blood
pressure, we repeated the analyses after stratification of the
cohort according to levels of oxidized LDL, a validated
marker of oxidative stress. The age- and sex-adjusted rela-
tionship between MPO and SBP by tertiles of oxidized LDL
revealed a pattern similar to that observed for glucose, with
the strongest association observed in individuals with high
levels of oxidized LDL, ie, the third tertile (0.92 [1.31
to 3.14], 2.00 [0.71 to 4.70], and 3.58 [0.98 to 6.19] for
increasing tertiles of oxidized LDL; Figure 2). Next, we
examined whether the relationship between MPO and SBP
was also modified by clinical or biochemical variables
Table 1. Subject Characteristics by Tertiles of MPO
MPO
Variable Unit
1st Tertile,
50.6 g/L
2nd Tertile,
50.6–62.7 g/L
3rd Tertile,
62.7 g/L P Value
N 248 249 249
Age Years 68.0 (7.1) 68.6 (6.9) 69.9 (7.4) 0.007
Sex, male % 56 46 47 0.054
Systolic blood pressure mm Hg 140 (19) 141 (21) 146 (21) 0.003
Diastolic blood pressure mm Hg 82 (10) 83 (11) 84 (11) 0.009
Hypertension % 53 56 64 0.016
C-reactive protein* mg/L 1.6 (0.9 to 2.8) 2.0 (1.1 to 4.2) 3.6 (1.7 to 6.9) 0.001
HbA1c % 6.0 (0.7) 6.1 (0.7) 6.2 (0.9) 0.001
Fasting glucose* mmol/L 6.0 (5.5 to 6.9) 6.0 (5.4 to 6.9) 6.3 (5.7 to 7.3) 0.001
Insulin* pmol/L 62 (44 to 84) 59 (41 to 86) 68 (46 to 101) 0.01
T2DM % 38 35 44 0.18
IGM % 25 25 26 0.94
BMI kg/m2 27.1 (3.6) 27.9 (4.3) 28.2 (4.7) 0.005
Waist circumference cm 95.1 (11.1) 96.7 (12.5) 97.7 (13.1) 0.002
LDL-cholesterol mmol/L 3.6 (1.0) 3.6 (0.9) 3.6 (0.9) 0.39
HDL-cholesterol mmol/L 1.34 (0.38) 1.43 (0.42) 1.37 (0.40) 0.97
Triglycerides* mmol/L 1.4 (1.0 to 1.8) 1.3 (1.0 to 1.9) 1.4 (1.0 to 1.9) 0.33
Oxidized LDL U/L 65.4 (15.6) 63.9 (14.5) 65.0 (15.5) 0.77
Microalbuminuria % 13 15 18 0.16
Prior cardiovascular disease % 46 46 55 0.048
Metabolic syndrome % 42 43 50 0.052
Current smoker % 10 20 16 0.053
Antihypertensive medication % 36 36 47 0.012
Lipid-lowering medication % 17 18 18 0.89
T2DM indicates type 2 diabetes; IGM, impaired glucose metabolism.
*Skewed variables were transformed by natural logarithm before trend analyses. P values represent trends across
tertiles and were obtained by age- and sex-adjusted linear regression analysis or, for dichotomous variables, by 2
linear-by-linear analyses.
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generally assumed to be associated with increased oxidative
stress, ie, low HDL-cholesterol, obesity, and the metabolic
syndrome. The concentration of HDL-cholesterol was in-
versely associated with oxidized LDL (0.25; P0.001),
whereas BMI was positively associated with oxidized LDL
(0.13; P0.001). The association between MPO and SBP
was strongest in subjects with HDL-cholesterol levels in the
lowest tertile (3.96 [1.52 to 6.39]) and in subjects with a
BMI in the highest tertile (3.52 [1.19 to 5.86] (Figure 2).
Levels of oxidized LDL were higher in individuals with the
metabolic syndrome compared to those without the metabolic
syndrome (69.916.1 and 60.613.1 U/L, respectively;
P0.001), and in the former group, the age- and sex-adjusted
association between MPO and blood pressure was strongest
Table 2. Multivariable Linear Regression Models of the Relation Between MPO and SBP in Strata of Fasting Glucose
Overall
1st Tertile Glucose,
5.8 mmol/L
2nd Tertile Glucose,
5.8 –6.5 mmol/L
3rd Tertile Glucose,
6.5 mmol/L
Model  (95% CI) P  (95% CI) P  (95% CI) P  (95% CI) P
Crude 2.53 (1.06 to 3.99) 0.001 1.04 (1.38 to 3.46) 0.40 1.88 (0.83 to 4.59) 0.17 3.82 (1.39 to 6.26) 0.002
Model 1: MPO*agesex 2.10 (0.66 to 3.54) 0.004 0.61 (1.70 to 2.93) 0.60 1.33 (1.43 to 4.10) 0.34 3.42 (1.01 to 5.82) 0.006
Model 1CRP* 1.69 (0.21 to 3.17) 0.025 0.03 (2.40 to 2.34) 0.98 1.36 (1.45 to 4.17) 0.34 3.31 (0.84 to 5.78) 0.009
Model 1glucose* 1.71 (0.28 to 3.14) 0.019 0.43 (1.87 to 2.73) 0.71 1.32 (1.45 to 4.10) 0.35 3.39 (0.96 to 5.82) 0.006
Model 1BMI 1.83 (0.40 to 3.25) 0.012 1.01 (1.21 to 3.23) 0.37 1.03 (1.74 to 3.79) 0.47 3.37 (0.95 to 5.79) 0.006
Model 1triglycerides* 2.12 (0.69 to 3.55) 0.004 0.64 (1.69 to 2.96) 0.59 1.32 (1.45 to 4.08) 0.35 3.48 (1.09 to 5.87) 0.005
Model 1microalbuminuria 2.05 (0.61 to 3.50) 0.005 0.57 (1.74 to 2.88) 0.63 1.23 (1.55 to 4.01) 0.39 3.44 (1.02 to 5.86) 0.005
Model 1prior cardiovascular
disease
2.05 (0.57 to 3.53) 0.007 0.59 (1.76 to 2.94) 0.63 1.35 (1.48 to 4.17) 0.35 3.33 (0.83 to 5.83) 0.009
Model 1current smoker 2.28 (0.84 to 3.73) 0.002 0.80 (1.51 to 3.11) 0.50 1.37 (1.38 to 4.13) 0.33 3.55 (1.09 to 6.01) 0.005
Model 1antihypertensive
medication
1.88 (0.44 to 3.31) 0.010 0.47 (1.81 to 2.75) 0.69 1.22 (1.56 to 3.99) 0.39 3.32 (0.91 to 5.73) 0.007
Model 1lipid-lowering
medication
2.10 (0.65 to 3.55) 0.005 0.61 (1.71 to 2.92) 0.61 1.32 (1.46 to 4.11) 0.35 3.38 (0.96 to 5.80) 0.006
Fully adjusted model† 1.61 (0.13 to 3.10) 0.033 0.26 (2.10 to 2.61) 0.83 1.11 (1.77 to 4.00) 0.45 3.50 (0.86 to 6.14) 0.010
 values represent increase in systolic blood pressure (mm Hg) per SD increase of MPO.
*Skewed variables were transformed by natural logarithm.
†Adjusted for age, sex, CRP, glucose, BMI, triglycerides, microalbuminuria, prior cardiovascular disease, current smoking, and use of antihypertensive and
lipid-lowering medication.
Table 3. Multivariable Linear Regression Models of the Relation Between MPO and DBP in Strata of Fasting Glucose
Overall
1st Tertile Glucose,
5.8 mmol/L
2nd Tertile Glucose,
5.8–6.5 mmol/L
3rd Tertile Glucose,
6.5 mmol/L
Model  (95% CI) P  (95% CI) P  (95% CI) P  (95% CI) P
Crude 0.85 (0.07 to 1.63) 0.033 0.09 (1.25 to 1.43) 0.90 0.26 (1.21 to 1.73) 0.73 1.66 (0.45 to 2.87) 0.008
Model 1: MPO*agesex 0.98 (0.20 to 1.76) 0.014 0.06 (1.29 to 1.40) 0.93 0.60 (0.89 to 2.10) 0.43 1.76 (0.54 to 2.98) 0.005
Model 1CRP* 0.83 (0.03 to 1.63) 0.043 0.16 (1.54 to 1.23) 0.83 0.71 (0.81 to 2.23) 0.36 1.67 (0.42 to 2.93) 0.009
Model 1glucose* 0.77 (0.00 to 1.55) 0.051 0.00 (1.35 to 1.35) 1.00 0.60 (0.90 to 2.10) 0.43 1.67 (0.45 to 2.90) 0.008
Model 1BMI 0.79 (0.03 to 1.55) 0.042 0.28 (1.01 to 1.58) 0.67 0.28 (1.18 to 1.74) 0.70 1.68 (0.46 to 2.90) 0.007
Model 1triglycerides* 0.99 (0.22 to 1.77) 0.012 0.03 (1.32 to 1.38) 0.96 0.57 (0.90 to 2.04) 0.45 1.78 (0.57 to 3.00) 0.004
Model 1microalbuminuria 0.94 (0.16 to 1.72) 0.018 0.01 (1.33 to 1.35) 0.98 0.57 (0.94 to 2.08) 0.46 1.78 (0.57 to 3.00) 0.004
Model 1prior cardiovascular
disease
0.97 (0.17 to 1.77) 0.017 0.05 (1.32 to 1.42) 0.94 0.57 (0.96 to 2.09) 0.47 1.73 (0.46 to 3.00) 0.008
Model 1current smoker 1.08 (0.30 to 1.86) 0.007 0.20 (1.14 to 1.53) 0.77 0.61 (0.89 to 2.12) 0.42 1.90 (0.66 to 3.14) 0.003
Model 1antihypertensive
medication
0.87 (0.09 to 1.64) 0.029 0.00 (1.34 to 1.33) 0.99 0.52 (0.97 to 2.02) 0.49 1.72 (0.49 to 2.94) 0.006
Model 1lipid-lowering
medication
0.98 (0.20 to 1.76) 0.014 0.05 (1.30 to 1.39) 0.95 0.60 (0.91 to 2.10) 0.43 1.76 (0.54 to 2.99) 0.005
Fully adjusted model† 0.81 (0.02 to 1.61) 0.045 0.07 (1.30 to 1.43) 0.92 0.43 (1.06 to 1.93) 0.57 1.82 (0.49 to 3.16) 0.008
 values represent increase in diastolic blood pressure (mm Hg) per SD increase of MPO.
*Skewed variables were transformed by natural logarithm.
†Adjusted for age, sex, CRP, glucose, BMI, triglycerides, microalbuminuria, prior cardiovascular disease, current smoking, and use of antihypertensive and
lipid-lowering medication.
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(2.47 [0.48 to 4.46] versus 1.17 [0.75 to 3.08] for SBP
and 1.64 [0.58 to 2.69] versus 0.06 [0.99 to 1.11] for
DBP).
The interaction between the effects of BMI and MPO on
SBP as shown in Figure 3 illustrates the clinical relevance of
the MPO-associated increase in blood pressure, especially in
subjects with a high BMI. The mean difference in SBP
between individuals with both BMI and MPO in the highest
tertile and individuals with both variables in the lowest tertile
was 14 mm Hg.
Discussion
The main finding of the current study is that the concentration
of MPO in the circulation was positively associated with both
SBP and DBP. This association was independent of tradi-
tional cardiovascular risk factors, including CRP, and use of
antihypertensive medication and was most prominent on a
background of hyperglycemia or oxidative stress.
Potential Mechanisms Linking MPO to
Blood Pressure
Local release by resident macrophages and transcytosis of
MPO produced by activated neutrophils that are attracted and
bound to sites of damaged endothelium are both sources of
MPO in the vascular wall. The microenvironment of the
subendothelial space of the vascular wall is especially con-
ducive to MPO activity. Mitochondrial respiration, NAD(P)H
oxidases, xanthine oxidase, and uncoupled nitric oxide syn-
thase (NOS) are major sources of the highly reactive super-
oxide radical, which is actively converted into hydrogen
peroxide by superoxide dismutase. Although less reactive
than the superoxide radical, hydrogen peroxide is the cosub-
strate for all MPO-catalyzed reactions. MPO amplifies the
oxidative potential of hydrogen peroxide by producing a
variety of reactive oxidants, including hypochlorous acid.9
Nitric oxide (NO), produced by endothelial NOS, is a
powerful vasodilator and as such plays a critical role in the
regulation of vascular tone. There are strong indications that
MPO, by several mechanisms, may reduce the bioavailability
of NO. First, NO serves as a substrate for peroxidases, and
MPO may thus serve as a catalytic sink for NO.20,21 Second,
scavenging of NO by MPO-derived reactive substances may
further reduce the bioavailability of NO. Third, hypochlorous
acid can react with nitrogen atoms of the NOS substrate
arginine to produce chlorinated arginine species that are
inhibitors of all isoforms of NOS and have been shown to
impair endothelium-dependent relaxation of rat aortic rings.22
Finally, it has been demonstrated that hypochlorous acid is a
potent inducer of uncoupling of endothelial NOS, thereby
turning NOS into a superoxide producing enzyme.23 Overall,
SBP
DBP
NGM
IGM
T2DM
NGM
IGM
T2DM
-3       -2       -1        0        1         2        3         4         5        6
Change of BP (mmHg) per 1-SD change of MPO
Figure 1. Effect of glucose metabolism on the relationship
between MPO and blood pressure. The relationships between
plasma concentrations of MPO and SBP and DBP in individuals
with normal glucose metabolism (NGM), impaired glucose me-
tabolism (IGM), and type 2 diabetes (T2DM) were obtained by
age- and sex-adjusted linear regression analyses. Regression
coefficients (95% CIs) are expressed as increase in blood pres-
sure (mm Hg) per 1 SD increase of log-transformed MPO.
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2
Figure 2. Impact of BMI and levels of fasting glucose, oxidized
LDL, and HDL-cholesterol on the relationship between MPO and
SBP. The relationships between plasma MPO and SBP were
obtained by age- and sex-adjusted linear regression analyses
after stratification by tertiles of the variable of interest. Regres-
sion coefficients (95% CIs) are expressed as increase in blood
pressure (mm Hg) per 1 SD increase of log-transformed MPO.
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Figure 3. Combined effect of obesity and MPO on blood pres-
sure. Bars represent unadjusted mean values of SBP after strat-
ification according to tertiles of BMI and tertiles of plasma MPO.
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reduction of NO bioavailability by MPO activity is a plausi-
ble mechanism for the adverse effect of MPO on blood
pressure. In addition, MPO-derived reactive substances may
damage the arterial wall and reduce its elasticity, thereby
contributing to hypertension.
Enhancement of the Relationship Between MPO
and Blood Pressure by Oxidative Stress
and Hyperglycemia
Because hydrogen peroxide is an obligate cosubstrate of
MPO, we hypothesized that the impact of MPO on blood
pressure would be most prominent on a background of
oxidative stress. This was confirmed by our observation that
the relationship between MPO and blood pressure was most
prominent in individuals with a high plasma concentration of
oxidized LDL. Our finding that high levels of fasting glucose
strengthened the association between MPO and blood pres-
sure is also compatible with this hypothesis, because high
glucose concentrations have been shown to stimulate vascular
production of reactive oxygen species.10,24 HDL particles are
known to have antiinflammatory and antioxidative proper-
ties.25 The observed decrease of the strength of the associa-
tion between MPO and blood pressure with increasing levels
of HDL-cholesterol is therefore also consistent with oxidative
stress as a modifying factor. A high BMI, which is related to
inflammation and oxidative stress,26,27 and the metabolic
syndrome, which captures much of the risk associated with
the above-mentioned variables, were also found to enhance
the relationship between MPO and blood pressure. Notably,
all conditions that strengthened the association between MPO
and blood pressure were associated with increased levels of
oxidized LDL. All in all, the results of these analyses point in
the same direction, ie, that the impact of MPO on blood
pressure is most prominent in the presence of (glucose-
induced) oxidative stress.
Potential Confounding of the Relationship Between
MPO and Blood Pressure by CRP
In contrast to the relationship between MPO and hypertension
that has hardly been studied on the population level, in
several studies an independent relationship between the
inflammation marker CRP and hypertension was ob-
served.28–31 Notably, CRP has been reported to stimulate
release of MPO from polymorphonuclear cells and mono-
cytes.32 This might indicate that the association between
MPO and blood pressure is, at least partly, not causal but
merely reflects the relationship between CRP and blood
pressure. Indeed, in the present study MPO and CRP were
significantly correlated, albeit with moderate strength. How-
ever, in the linear regression models, the association between
MPO and blood pressure was only slightly attenuated on
adjustment for CRP, indicating that confounding of this
association by CRP is of minor significance. Most likely,
different mechanisms are involved in the associations of
MPO and CRP with hypertension. This is consistent with
CRP being mainly produced by the liver on stimulation by
inflammatory cytokines, whereas MPO is locally produced at
sites of inflammation including the vasculature.
Study Limitations
First, although a causal relationship between MPO and blood
pressure is plausible, we used a cross-sectional design, which
does not allow us to draw definitive conclusions on causality.
Second, although the original study population was recruited
from the general population, for the present study a selection
was made on the basis of glucose metabolism, ie, individuals
with impaired glucose metabolism and type 2 diabetes were
overrepresented. This design made this cohort very suitable to
investigate the impact of (glucose-induced) oxidative stress
on the relationship between MPO and hypertension. How-
ever, we cannot exclude the possibility that selection bias has
influenced the relationship between MPO and blood pressure.
Third, the study was performed in elderly white subjects, and
the association between MPO and blood pressure may be
different in younger individuals and other races. Fourth, MPO
was measured in the circulation, and it is currently not known
to what extent this measure reflects MPO in the vasculature.
Finally, we measured MPO mass and not activity. However,
a strong correlation between MPO mass and MPO activity
(r0.95) has been reported.33
Perspectives
The current study demonstrates that a high plasma level of
MPO is associated with a clinically relevant increase in both
SBP and DBP. The relationship between MPO and blood
pressure is particularly prominent on a background of hyper-
glycemia or oxidative stress, consistent with the ability of
MPO to amplify oxidative stress, eg, by using hydrogen
peroxide as a cosubstrate to form more reactive oxidant
species. The relationship between MPO and hypertension,
together with emerging evidence that MPO-derived oxidants
contribute to initiation and propagation of acute and chronic
vascular disease,4–8 identifies MPO as an interesting target
for drug development. However, because MPO plays an
important role in the innate immune system, a suitable
inhibitor should specifically target activity of MPO in the
vascular wall, without interfering with its bactericidal activ-
ity.34 Possibly, this selectivity may be achieved by lowering
vascular oxidative stress and thereby the local concentration
of hydrogen peroxide, the cosubstrate of MPO.
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